Woźniak Krzysztof, Sachs Wojciech, Boguradzki Piotr, Basak Grzegorz Władysław, Stec Rafał
Department of Oncology, Medical University of Warsaw, Warsaw, Poland.
Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Front Oncol. 2021 Apr 12;11:662211. doi: 10.3389/fonc.2021.662211. eCollection 2021.
COVID-19 has become the biggest public health problem and one of the most important causes of death in many countries in the world. SARS-CoV-2 infection is most likely to be fatal in elderly patients with concomitant diseases. In this article we present two cases of asymptomatic SARS-CoV-2-positive patients suffering from cancer who were treated with chemotherapy. The first case, a patient with primary mediastinal B-cell lymphoma, shows that confirmed SARS-CoV-2 infection does not have to be a contraindication to chemotherapy. We describe the course of disease and discuss doubts related to the choice of chemotherapy regimen. The second patient was a male with metastatic sigmoid cancer treated with FOLFOX4 as first-line palliative chemotherapy. This case draws attention to asymptomatic SARS-CoV-2 carriers who underwent chemotherapy. Our patient was safely treated with chemotherapy without long break caused by viral infection. It should be remembered that there are asymptomatic carriers among cancer patients and that they may spread infection to others. On the other hand, delaying chemotherapy can cause rapid disease progression and reduce overall survival of our patients.
新型冠状病毒肺炎(COVID-19)已成为全球许多国家最大的公共卫生问题及最重要的死因之一。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染在患有合并症的老年患者中最有可能致命。在本文中,我们展示了两例患有癌症的无症状SARS-CoV-2阳性患者接受化疗的病例。第一例是一名原发性纵隔B细胞淋巴瘤患者,表明确诊的SARS-CoV-2感染不一定是化疗的禁忌证。我们描述了疾病的病程,并讨论了与化疗方案选择相关的疑问。第二例患者是一名患有转移性乙状结肠癌的男性,接受FOLFOX4作为一线姑息化疗。该病例引起了对接受化疗的无症状SARS-CoV-2携带者的关注。我们的患者在没有因病毒感染导致长时间中断的情况下安全地接受了化疗。应该记住,癌症患者中存在无症状携带者,他们可能会将感染传播给他人。另一方面,延迟化疗会导致疾病快速进展并降低我们患者的总生存期。